PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34183306-1	2021	Isocitrate dehydrogenase (IDH) mutations produce high levels of the "oncometabolite" R-2-hydroxyglutarate (R-2-HG) and play a key role in the initiation and progression of glioma tumors in the brain.	r-2-hg	107-113	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	0-24	
34183306-1	2021	Isocitrate dehydrogenase (IDH) mutations produce high levels of the "oncometabolite" R-2-hydroxyglutarate (R-2-HG) and play a key role in the initiation and progression of glioma tumors in the brain.	r-2-hg	107-113	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	26-29	
34183306-3	2021	describes how IDH-mutant-derived R-2-HG elicits an immunosuppressive phenotype in glioma-associated macrophages.	r-2-hg	33-39	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	14-17	
34188585-3	2021	A mutant IDH enzyme, existing in the cell cytoplasm and possessing neomorphic activity, converts alphaKG into oncometabolite R-2-hydroxyglutarate (R-2-HG) that accumulates in high amounts in the cell and inhibits alphaKG-dependent enzymes, including epigenetic regulators.	r-2-hg	147-153	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	9-12	
32955829-3	2020	Mutant IDH enzymes have neomorphic activity and convert alphaKG to the oncometabolite R-2-hydroxyglutarate (R-2-HG) which accumulates at high levels in the cell and hampers the function of alphaKG-dependent enzymes, including epigenetic regulators, thus leading to altered gene expression and block of differentiation and contributing to leukemia development.	r-2-hg	108-114	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	7-10	
32859092-4	2020	Among these alterations, an important role is played by two mutant enzymes of the citric acid cycle, isocitrate dehydrogenase (IDH), IDH1 and IDH2, occurring in about 20% of AMLs, which leads to the production of an oncogenic metabolite R-2-hydroxy-glutarate (R-2-HG); this causes a DNA hypermethylation and an inhibition of hematopoietic stem cell differentiation.	r-2-hg	260-266	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	101-125	
32859092-4	2020	Among these alterations, an important role is played by two mutant enzymes of the citric acid cycle, isocitrate dehydrogenase (IDH), IDH1 and IDH2, occurring in about 20% of AMLs, which leads to the production of an oncogenic metabolite R-2-hydroxy-glutarate (R-2-HG); this causes a DNA hypermethylation and an inhibition of hematopoietic stem cell differentiation.	r-2-hg	260-266	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	127-130	
32859092-4	2020	Among these alterations, an important role is played by two mutant enzymes of the citric acid cycle, isocitrate dehydrogenase (IDH), IDH1 and IDH2, occurring in about 20% of AMLs, which leads to the production of an oncogenic metabolite R-2-hydroxy-glutarate (R-2-HG); this causes a DNA hypermethylation and an inhibition of hematopoietic stem cell differentiation.	r-2-hg	260-266	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	133-137	
29988124-1	2018	The oncometabolite (R)-2-hydroxyglutarate (R-2-HG) produced by isocitrate dehydrogenase (IDH) mutations promotes gliomagenesis via DNA and histone methylation.	r-2-hg	43-49	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	63-87	
29988124-1	2018	The oncometabolite (R)-2-hydroxyglutarate (R-2-HG) produced by isocitrate dehydrogenase (IDH) mutations promotes gliomagenesis via DNA and histone methylation.	r-2-hg	43-49	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	89-92